1 / 25

Dengue: A Global Threat Audience: United States International Travelers

Dengue: A Global Threat Audience: United States International Travelers Arkia Blackman, MPH student Walden University PUBH 6165-5 Environmental Health Instructor: Dr. Donald Goodwin Spring, 2010. Agenda. Definition Modes of Transmission Serotypes Classification Contributing factors

oliver-cameron
Download Presentation

Dengue: A Global Threat Audience: United States International Travelers

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Dengue: A Global Threat Audience: United States International Travelers Arkia Blackman, MPH student Walden University PUBH 6165-5 Environmental Health Instructor: Dr. Donald Goodwin Spring, 2010

  2. Agenda • Definition • Modes of Transmission • Serotypes • Classification • Contributing factors • Statistics • Prevention • Treatment • Tips for travelers • Blood transfusion

  3. Definition What is Dengue? Dengue is a virus consisting of a single-stranded Ribonucleic Acid (RNA) (Thomas, John & Kanish, 2010). The virus genetic makeup consist of a lipid envelope protein that enables it to transport and bind in possible hosts (Teo, Ng & Lam, 2009).

  4. Modes of Transmission • Vector borne transmission • Mosquito • Non vector borne transmission • Mother to child (Wiwanitki, 2010). • Blood transfusion (Wiwanitki, 2010). • Organ transplantation (Wiwanitki, 2010).

  5. Mode of Transmission Aedes Aegypti(Teo et al., 2009) Aedes albopictus (Teo et al., 2009) Aedes polynesiensis (Teo et al., 2009)

  6. Modes of Transmission • Dengue is transmitted primarily by the mosquito family Aedes Aegypti (Teo et al., 2009). • Dengue can also be transmitted by mosquito family Aedes albopictus and Aedespolynesiensis(Teo et al., 2009). • A female mosquito bite leads to an infection of Dengue then is transmitted into other victims in a constant cycle. • The incubation period of the infection varies 7-14 days(Teo et al., 2009). • The mosquito biting period occurs primarily in the dawn and at dusk(Teo et al., 2009).

  7. Modes of Transmission • Mother to child transmission • Can occur during a woman’s late term of their pregnancy through the placenta (Wiwanitki,2010). • Transmission through transfusion of blood and blood products (Wiwantiki, 2010). • Transplantation of Dengue infected organs(Wiwantiki, 2010).

  8. Serotypes • There are four serotypes of dengue (Teo et al., 2009). • Den-1 • Den-2 • Den-3 • Den-4 • Infection of one serotype does not ensure immunity against the other serotypes (Teo et al., 2009). • The serotypes are independent of each other (Teo et al., 2009).

  9. Classification • Dengue fever • Classified as individuals with symptoms such as headache, rash, leukopenia or myalgia along with the serological confirmation or in an areawith similarcases (Thomas et al., 2010). • Dengue hemorrhagic fever • Classified by a previous or current fever lasting 2-7 days, bleeding such as hematemesis, a high thrombocytopenia count, and evidence of plasma leakage (Thomas et al., 2010). • Dengue shock syndrome • Classified as having all the symptoms of dengue hemorrhagic fever and failure to the circulatory system (Thomas et al., 2010).

  10. Contributing Factors • Population growth (Teo et al., 2009) • Ineffective mosquito control (Teo et al., 2009) • Global travel (Teo et al., 2009) • Poor water management (Teo et al., 2009)

  11. Statistics • 2.5 billion individuals are at risk globally (CDC, 2010). • 100 million individuals become affected with dengue fever annually (CDC, 2010) • Children make up the majority of the 500,000 cases of the fatal dengue hemorrhagic fever (CDC, 2010).

  12. Statistics • Dengue is the second highest disease among travelers hospitalized after travel to tropical areas (Tomashek, 2009) • Individuals that travel to dengue-endemic countries suffer an infection rate of 2.9% to 8% (Tomashek, 2009) • Dengue is the number one disease for individuals that travel to South Central Asia, Southeast Asia, Caribbean and South America (Tomashek, 2009).

  13. Prevention • Environmental control involves reducing or eliminating breeding grounds for mosquitoes by properly managing solid waste ina community or country (Gurugama, Garg, Perera, Wijewickrama & Seneviratne, 2010). • Chemical control involves the use of insecticides to target the larvae state of mosquito lifecycle or thermal fogging which is a form of spraying in the household(Gurugama et al., 2010).

  14. NO VACCINE AVAILABLE

  15. Treatment • Dengue without warning signs • Treatment include proper bed rest, replenishment of fluids and proper dosage of the drug Paracetamol(World Health Organization [WHO], 2009). • Dengue with warning signs • Treatment include fluid therapy as prescribedby medical personnel(WHO, 2009). • Severe Dengue • Treatment consist of fluid resuscitation with isotonic crystalloid solutions(WHO, 2009).

  16. Prevention • Vaccines are being created and are in clinical studies so that they can be tested and researched for safety and effectiveness(Guzman, Vazquez & Kouri, 2009) • Some issues with creating vaccines include the differences between the four serotypes which may require different types of vaccine instead of one and the lack of an animal researchsubject(Guzman et al. 2009)

  17. Tips for Travelers • Sleeping accommodations • Travelers should ensure they are staying in accommodations that have air conditioning available and windows are appropriately screened (Tomashek, 2009). • Clothing • Travelers should wear clothing that protects exposed areas such as legs and arms to ensure mosquitoes do not have easyaccess to bite and transmit the dengue virus(Tomashek, 2009). • Insect Repellant • Repellant is very important and necessary when traveling to areas that are endemic to dengue. The repellant should be used on clothes and areas of the skin (Tomashek, 2009).

  18. Blood Transfusions • Donor qualification • Due to the rise of dengue infection in endemic countries and among travelers the individuals can be deferred from donating blood to prevent the risk of transfusion related transmissionof dengue(Teo et al., 2009). • In various countries blood donors are being deferred for 6 months and 2-3 weeks and this diminishes the number of blood donations available for emergency and routine use(Teo et al., 2009). • NAT testing • The cost of NAT testing for dengue will be expensive and necessary to detect dengue in blood donations to ensure there is a safe blood supply (Teo et al., 2009).

  19. Summary • Dengue is a virus transmitted by vector and non vector methods • There are 3 types of dengue disease, dengue fever, dengue hemorrhagic fever and dengue shock syndrome • Travelersneed to protect themselves when traveling to prevent infection of dengue • No vaccine is available for use currently • Blood donations are at risk

  20. Questions

  21. References Center for Disease Control. (2010). Dengue-A Worldwide Threat. The Dengue Update. Volume 1. Retrieved on April 24, 2010, from http://www.cdc.gov/dengue/dengue_upd/index.html Gurugama, P., Garg, P., Perera, J., Wijewickrama, A., & Seneviratne S. L. (2010). Dengue Viral Infections. Indian Journal of Dermatology, 55(1), 68-78. DOI: 10.4102/0019 5154.60357. Guzman M. G., Vazquez, S. & Kouri, G. (2009). Dengue: where are we today? Malaysian Journal of Medical Sciences, 16(3), 5-12. Retrieved from Academic Search Complete Database Teo D., Ng L. C., & Lam, S. (2009). Is dengue a threat to the blood supply? Transfusion Medicine, 19, 66-77. doi: 10.111/j.1365-3148.2009.00916.x

  22. References Thomas E. A., John, M., & Kanish B. (2010). Mucocutaneous Manifestations of Dengue Fever. Indian Journal of Dermatology, 55(1), 79-85. DOI: 10.4103/0019-5154.60359. Tomashek, K. M. (2009). Dengue Fever (DF) and Dengue Hemorrhagic Fever (DHF). Retrieved April 25, 2010, from http://wwwnc.cdc.gov/travel/yellowbook/2010/chapter-5/dengue-fever-dengue-hemorrhagic-fever.aspx Wiwanitkit, V. (2010). Non vector-borne transmission modes of dengue. Journal of Infection In Developing Countries, 4(1), 051-054. Retrieved from Academic Search Complete Database.

  23. References World Health Organization. (2009). Dengue Guidelines for Diagnosis,Treatment, Prevention and Control. Retrieved April 24, 2010, from http://whqlibdoc.who.int/publications/2009/97892 1547871_eng.pdf

  24. Sources to Read • For information on insect repellants such as how to use them, when to use and why to use them check out the following site • Centers for Disease Control and Prevention. Insect Repellent Use and Safety; [updated 2008 May 14; cited 2008 Nov 29]. Available from: www.cdc.gov/ncidod/dvbid/westnile/qa/insect_repellent.htm. • For additional information on insect repellants and which ones are registered and unregistered and alternative preventative measures please visit this site on the U.S. Environmental Protection Agency • U.S. Environmental Protection Agency. How to Use Insect Repellents Safely; [updated 2007 July 5; cited 2008 Nov 29]. Available from: www.epa.gov/pesticides/health/mosquitoes/insectrp.htm.

  25. Sources to Read • For information on the research being conducted to create a vaccine and the progress and challenges of this effort please read the following article • Swaminathan, S. & Khanna, N. (2010). Dengue vaccine current progress and challenges. Current Science. 98(3):369-378

More Related